[go: up one dir, main page]

MX2011011511A - Sal de abt-263 y fomas en estado solido de la misma. - Google Patents

Sal de abt-263 y fomas en estado solido de la misma.

Info

Publication number
MX2011011511A
MX2011011511A MX2011011511A MX2011011511A MX2011011511A MX 2011011511 A MX2011011511 A MX 2011011511A MX 2011011511 A MX2011011511 A MX 2011011511A MX 2011011511 A MX2011011511 A MX 2011011511A MX 2011011511 A MX2011011511 A MX 2011011511A
Authority
MX
Mexico
Prior art keywords
abt
salt
solid
state forms
overexpression
Prior art date
Application number
MX2011011511A
Other languages
English (en)
Inventor
Thomas Borchardt
Rodger Henry
Geoff Zhang
Xiaochun Lou
Nathaniel Catron
Deliang Zhou
Paul Brackemyer
Matthew Ravn
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2011011511A publication Critical patent/MX2011011511A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Bis-HCI de ABT-263 y los polimorfos cristalinos del mismo son ingredientes farmacéuticos activos apropiados para composiciones farmacéuticas útiles en el tratamiento de una enfermedad caracterizada por sobre-expresión de una o más proteínas anti-apoptóticas de la familia de BcI-2, por ejemplo cáncer.
MX2011011511A 2009-04-30 2010-04-30 Sal de abt-263 y fomas en estado solido de la misma. MX2011011511A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17427409P 2009-04-30 2009-04-30
PCT/US2010/033072 WO2010127190A1 (en) 2009-04-30 2010-04-30 Salt of abt-263 and solid-state forms thereof

Publications (1)

Publication Number Publication Date
MX2011011511A true MX2011011511A (es) 2011-11-18

Family

ID=42288743

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011511A MX2011011511A (es) 2009-04-30 2010-04-30 Sal de abt-263 y fomas en estado solido de la misma.

Country Status (17)

Country Link
US (1) US8362013B2 (es)
EP (1) EP2424849A1 (es)
JP (1) JP2012525433A (es)
KR (1) KR20120005538A (es)
CN (1) CN102414186A (es)
AR (1) AR076509A1 (es)
AU (1) AU2010242923A1 (es)
BR (1) BRPI1014369A2 (es)
CA (1) CA2758740A1 (es)
IL (1) IL215472A0 (es)
MX (1) MX2011011511A (es)
RU (1) RU2011148521A (es)
SG (1) SG175146A1 (es)
TW (1) TW201041882A (es)
UY (1) UY32598A (es)
WO (1) WO2010127190A1 (es)
ZA (1) ZA201107592B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100280031A1 (en) * 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
US8362013B2 (en) 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
TWI471321B (zh) * 2009-06-08 2015-02-01 亞培公司 Ｂｃｌ－２族群抑制劑之口服醫藥劑型
EP2477972A1 (en) * 2009-09-20 2012-07-25 Abbott Laboratories Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases
US8927009B2 (en) * 2009-12-22 2015-01-06 Abbvie Inc. ABT-263 capsule
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CN102584744B (zh) * 2011-01-06 2015-07-01 上海药明康德新药开发有限公司 4-(4-((2-(4-氯苯基)-5,5-二甲基环己基-1-烯)甲基)哌嗪-1-基)苯甲酸的合成方法
NZ715776A (en) 2013-07-30 2017-04-28 Gilead Connecticut Inc Polymorph of syk inhibitors
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
US9993472B2 (en) * 2014-01-28 2018-06-12 Unity Biotechnology, Inc. Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2
US20170202782A1 (en) * 2014-04-06 2017-07-20 Abraxis Bioscience, Llc Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer
MX2017000610A (es) 2014-07-14 2017-04-27 Gilead Sciences Inc Metodos combinados para tratar canceres.
TW201639573A (zh) 2015-02-03 2016-11-16 吉李德科學股份有限公司 有關治療癌症之合併治療
US20180133212A1 (en) 2016-11-03 2018-05-17 Gilead Sciences, Inc. Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer
US11384082B2 (en) 2017-08-25 2022-07-12 Kronos Bio, Inc. Hydrates of polymorphs of 6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)-2,3-dihydroimidazo[1,2-A]pyrazin-8-amine bisemsylate as Syk inhibitors
CN113950479A (zh) 2019-02-22 2022-01-18 克洛诺斯生物股份有限公司 作为syk抑制剂的缩合吡嗪的固体形式
BR112022008683A2 (pt) 2019-11-05 2022-07-19 Abbvie Inc Regimes de dosagem para uso no tratamento de mielofibrose e distúrbios relacionados a mpn com navitoclax
US20230157970A1 (en) * 2021-11-19 2023-05-25 Board Of Regents, The University Of Texas System Targeted Therapy of Kidney Fibrosis

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US630663A (en) * 1899-05-01 1899-08-08 Wallace George Cook Combined hay and stock rack.
US5665379A (en) 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
US5536729A (en) 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
IL111004A (en) 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
US5759548A (en) 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5538737A (en) 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
US6964946B1 (en) 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
BE1011899A6 (fr) 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
CA2606147C (en) 2005-05-12 2011-07-05 Abbott Laboratories Apoptosis promoters
US20070104780A1 (en) * 2005-10-25 2007-05-10 Lipari John M Formulation comprising a drug of low water solubility and method of use thereof
CA2708223A1 (en) 2007-12-06 2009-06-11 Andrew Krivoshik Oral compositions of abt-263 for treating cancer
CN101220008B (zh) 2008-01-21 2011-04-27 中国科学院广州生物医药与健康研究院 化合物abt-263的合成方法
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
US20100297194A1 (en) 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US20100278921A1 (en) 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US8728516B2 (en) 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US8362013B2 (en) 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
KR20120052937A (ko) 2009-06-18 2012-05-24 아보트 러보러터리즈 안정한 나노입자형 약물 현탁액
EP2477972A1 (en) 2009-09-20 2012-07-25 Abbott Laboratories Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases
CN101798292A (zh) 2010-03-29 2010-08-11 无锡好芳德药业有限公司 ABT-263衍生的新型Bcl-2蛋白抑制剂的制备

Also Published As

Publication number Publication date
JP2012525433A (ja) 2012-10-22
US8362013B2 (en) 2013-01-29
AR076509A1 (es) 2011-06-15
KR20120005538A (ko) 2012-01-16
BRPI1014369A2 (pt) 2016-04-05
ZA201107592B (en) 2012-06-27
EP2424849A1 (en) 2012-03-07
CA2758740A1 (en) 2010-11-04
WO2010127190A1 (en) 2010-11-04
IL215472A0 (en) 2011-12-29
SG175146A1 (en) 2011-11-28
TW201041882A (en) 2010-12-01
CN102414186A (zh) 2012-04-11
US20100305125A1 (en) 2010-12-02
UY32598A (es) 2010-12-31
AU2010242923A1 (en) 2011-11-17
RU2011148521A (ru) 2013-06-10

Similar Documents

Publication Publication Date Title
MX2011011511A (es) Sal de abt-263 y fomas en estado solido de la misma.
MX2012003408A (es) Formas cristalinas de abt-263 y solvatos para uso para tratar enfermedades relacionadas con la proteina bcl-2.
EA017091B9 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
NZ596047A (en) Stabilized lipid formulation of apoptosis promoter
MY158932A (en) Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
MX2010009163A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211.
UA96964C2 (ru) Соединения полициклической мочевины с антибактериальными свойствами
MX2012004148A (es) Compuestos de dioxido de iminotiadiazina como inhibidores de la enzima de disociacion de la proteina precursora amiloide en el sitio beta, composiciones, y su uso.
MX2007010072A (es) Derivados de piperidina antibacterianos.
PH12015500297A1 (en) Adoptosis-inducing agents for the treatment of cancer and immune and automoimmune disease
PH12012500622A1 (en) Compounds for the treatment of dyslipidemia and related diseases
IN2012DN03328A (es)
IN2012DN02139A (es)
IL211120A (en) Compound, tetracycline converted at position 7c with fluorine, a pharmaceutical preparation containing it and its use in the preparation of drugs for the treatment of bacteria-caused infection
WO2010139979A3 (en) Processes for preparing crystalline forms of dasatinib
MX2009013501A (es) Compuestos piperidinicos y sus usos.
EP2583969A4 (en) NEW RHODANINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS WITH THE RHODANIN DERIVATIVES AS ACTIVE AGENTS
MX2010013310A (es) Derivados de heterociclil urea para el tratamiento de infecciones bacterianas.
WO2011069037A3 (en) Stabilization and storage of biological pharmaceutical compositions
EA201001859A1 (ru) Гетероциклические производные мочевины и способы их применеия
MX2012007325A (es) Capsula de abt-263.
NZ596527A (en) Nitrile derivatives and their pharmaceutical use and compositions
TW200800993A (en) Organic compounds
IL218388A (en) Hydroxyphenyl compounds, pharmaceuticals containing them, their use in the treatment of antimicrobial infections, their preparation and intermediates in the process
TN2011000617A1 (en) 17 - alkyl-17 -oxy-oestratrienes

Legal Events

Date Code Title Description
FA Abandonment or withdrawal